European approval for combination lumacaftor/ivacaftor paediatric cystic fibrosis drug
A paediatric treatment for 2 to 5 year olds has been approved by the European Commission to treat children with the most common form of cystic fibrosis...
List view / Grid view
A paediatric treatment for 2 to 5 year olds has been approved by the European Commission to treat children with the most common form of cystic fibrosis...